|View printer-friendly version|
|August 21, 2006 1:56 p.m.|
|Teva Announces Health Canada Approves Azilect® (Rasagiline) for Parkinson's Disease|
Approved in Canada as Monotherapy in Early PD and as an Adjunct to Levodopa in Moderate-to-Advanced Disease
Jerusalem, Israel, August 21, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that AZILECT® (rasagiline tablets), the first once daily oral treatment for Parkinson's disease (PD) has just been approved by Health Canada. The drug is approved for use as initial monotherapy in early Parkinson's disease and as adjunct therapy to levodopa in moderate to advanced disease. AZILECT® is expected to become available in Canada this September.